HC Wainwright Reaffirms "Buy" Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report)'s stock had its "buy" rating reissued by analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They presently have a $100.00 price objective on the stock. HC Wainwright's price objective suggests a potential upside of 151.83% from the stock's previous close. HC Wainwright also issued estimates for MoonLake Immunotherapeutics' Q1 2026 earnings at ($0.81) EPS, Q2 2026 earnings at ($0.87) EPS, Q3 2026 earnings at ($0.93) EPS, Q4 2026 earnings at ($1.00) EPS and FY2026 earnings at ($3.62) EPS.

MLTX has been the topic of several other reports. Wedbush restated an "outperform" rating and issued a $73.00 price target (down from $92.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, November 5th. The Goldman Sachs Group raised MoonLake Immunotherapeutics from a "neutral" rating to a "buy" rating and lifted their target price for the company from $62.00 to $82.00 in a research report on Friday, January 17th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $83.20.

MoonLake Immunotherapeutics Price Performance

Shares of MLTX traded down $2.05 during trading hours on Thursday, hitting $39.71. The stock had a trading volume of 218,019 shares, compared to its average volume of 434,238. The stock has a market capitalization of $2.54 billion, a price-to-earnings ratio of -30.78 and a beta of 1.28. MoonLake Immunotherapeutics has a 52 week low of $37.55 and a 52 week high of $58.26. The company's fifty day moving average is $46.49 and its two-hundred day moving average is $48.95.

Remove Ads

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.09). Equities analysts predict that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

Several institutional investors have recently made changes to their positions in MLTX. Congress Asset Management Co. bought a new position in MoonLake Immunotherapeutics in the third quarter valued at approximately $3,360,000. US Bancorp DE bought a new position in shares of MoonLake Immunotherapeutics during the third quarter worth about $44,000. Rice Hall James & Associates LLC acquired a new position in MoonLake Immunotherapeutics in the third quarter valued at $3,805,000. Harbor Capital Advisors Inc. boosted its holdings in shares of MoonLake Immunotherapeutics by 100.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 77,468 shares of the company's stock worth $3,906,000 after buying an additional 38,779 shares in the last quarter. Finally, AlphaCentric Advisors LLC bought a new position in shares of MoonLake Immunotherapeutics during the 3rd quarter worth about $706,000. 93.85% of the stock is currently owned by institutional investors.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.